PHAS.Q Stock Overview
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
PhaseBio Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.04 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | -99.00% |
| 1 Year Change | -99.88% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
PhaseBio Pharmaceuticals GAAP EPS of -$0.34 misses by $0.03, revenue of $0.21M misses by $0.29M
Aug 12PhaseBio Pharmaceuticals (NASDAQ:PHAS) Has Debt But No Earnings; Should You Worry?
Aug 10
PhaseBio shares surge after inking exclusive license agreement for bentracimab
Jun 17What Kind Of Shareholders Hold The Majority In PhaseBio Pharmaceuticals, Inc.'s (NASDAQ:PHAS) Shares?
Mar 04If You Had Bought PhaseBio Pharmaceuticals' (NASDAQ:PHAS) Shares A Year Ago You Would Be Down 28%
Jan 08PhaseBio Pharmaceuticals EPS misses by $0.15
Nov 12Shareholder Returns
| PHAS.Q | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -4.2% | -3.7% |
| 1Y | -99.9% | -2.0% | 20.5% |
Return vs Industry: PHAS.Q underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: PHAS.Q underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| PHAS.Q volatility | |
|---|---|
| PHAS.Q Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PHAS.Q's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine PHAS.Q's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 60 | Jonathan Mow | phasebio.com |
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension.
PhaseBio Pharmaceuticals, Inc. Fundamentals Summary
| PHAS.Q fundamental statistics | |
|---|---|
| Market cap | US$49.00 |
| Earnings (TTM) | -US$102.84m |
| Revenue (TTM) | US$818.00k |
0.0x
P/S Ratio0.0x
P/E RatioIs PHAS.Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHAS.Q income statement (TTM) | |
|---|---|
| Revenue | US$818.00k |
| Cost of Revenue | US$87.70m |
| Gross Profit | -US$86.88m |
| Other Expenses | US$15.96m |
| Earnings | -US$102.84m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did PHAS.Q perform over the long term?
See historical performance and comparison